Grace Therapeutics annual r&d spending
2019
2020
2021
2022
2023
2024
2025
2026
Grace Therapeutics R&D Spending Growth & History (GRCE)
Grace Therapeutics's r&d spending was $2.4M for fiscal 2026.
View full Grace Therapeutics company overviewGrace Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | $2.4M | −$7.1M | −74.71% |
| 2025 | 2025-03-31 | $9.5M | $4.8M | +103.10% |
| 2024 | 2024-03-31 | $4.7M | −$5.3M | −53.04% |
| 2023 | 2023-03-31 | $10.0M | $4.4M | +79.38% |
| 2022 | 2022-03-31 | $5.6M | $1.4M | +33.21% |
| 2021 | 2021-03-31 | $4.2M | −$11.8M | −73.88% |
| 2020 | 2020-03-31 | $16.0M | −$13.4M | −45.62% |
| 2019 | 2019-03-31 | $29.4M | — | — |
Grace Therapeutics quarterly r&d spending
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | $697,000 | −$258,000 | −27.02% |
| Q4 2026 | 2026-03-31 | $420,000 | −$1.2M | −74.28% |
| Q3 2026 | 2025-12-31 | $462,000 | −$1.7M | −78.94% |
| Q2 2026 | 2025-09-30 | $568,000 | −$2.4M | −80.91% |
| Q1 2026 | 2025-06-30 | $955,000 | −$1.8M | −64.73% |
| Q4 2025 | 2025-03-31 | $1.6M | −$52,000 | −3.09% |
| Q3 2025 | 2024-12-31 | $2.2M | $751,000 | +52.04% |
| Q2 2025 | 2024-09-30 | $3.0M | $2.5M | +546.96% |
| Q1 2025 | 2024-06-30 | $2.7M | $1.6M | +147.31% |
| Q4 2024 | 2024-03-31 | $1.7M | $45,000 | +2.74% |
| Q3 2024 | 2023-12-31 | $1.4M | −$1.0M | −41.10% |
| Q2 2024 | 2023-09-30 | $460,000 | −$2.8M | −86.03% |
| Q1 2024 | 2023-06-30 | $1.1M | −$1.5M | −57.72% |
| Q4 2023 | 2023-03-31 | $1.6M | −$686,000 | −29.49% |
| Q3 2023 | 2022-12-31 | $2.5M | $271,000 | +12.44% |
| Q2 2023 | 2022-09-30 | $3.3M | $2.7M | +462.74% |
| Q1 2023 | 2022-06-30 | $2.6M | $2.1M | +452.24% |
| Q4 2022 | 2022-03-31 | $2.3M | $1.9M | +413.47% |
| Q3 2022 | 2021-12-31 | $2.2M | $1.5M | +221.39% |
| Q2 2022 | 2021-09-30 | $585,000 | −$701,000 | −54.51% |
| Q1 2022 | 2021-06-30 | $469,000 | −$1.3M | −73.29% |
| Q4 2021 | 2021-03-31 | $453,000 | −$1.5M | −76.38% |
| Q3 2021 | 2020-12-31 | $678,000 | −$3.2M | −82.67% |
| Q2 2021 | 2020-09-30 | $1.3M | −$2.7M | −67.48% |
| Q1 2021 | 2020-06-30 | $1.8M | −$4.4M | −71.63% |
| Q4 2020 | 2020-03-31 | $1.9M | — | — |
| Q3 2020 | 2019-12-31 | $3.9M | — | — |
| Q2 2020 | 2019-09-30 | $4.0M | — | — |
| Q1 2020 | 2019-06-30 | $6.2M | — | — |
Grace Therapeutics r&d spending trends
Over the last five fiscal years, Grace Therapeutics's r&d spending decreased from $4.2M to $2.4M, a change of −$1.8M. The latest reported quarter, Q1 2027, shows $697,000.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Grace Therapeutics source filings ↗